With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

Funnyman Kenan Thompson is opening up about the not-so-funny experience of living with gastroesophageal reflux disease (GERD) ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Several pharma CEOs met with Chinese President Xi Jinping in Beijing. President Donald Trump's reciprocal tariffs have mostly ...

Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to multiple reports.

But at the same time, industry leaders are bracing for the news that they think is inevitable given Trump’s declaration in February to impose “25% or higher” levies on imported drugs.